Last reviewed · How we verify
Omega 3-Atorvastatin
Omega-3 fatty acids reduce triglycerides and inflammation while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol.
Omega-3 fatty acids reduce triglycerides and inflammation while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol. Used for Hyperlipidemia and hypertriglyceridemia, Cardiovascular disease prevention.
At a glance
| Generic name | Omega 3-Atorvastatin |
|---|---|
| Also known as | Atmeg-Omethyl cutielet, Atmeg |
| Sponsor | Seoul National University Bundang Hospital |
| Drug class | Statin + omega-3 fatty acid combination |
| Target | HMG-CoA reductase (atorvastatin); GPR120, GPR40 (omega-3 signaling) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This combination drug leverages omega-3 polyunsaturated fatty acids (EPA/DHA) to decrease plasma triglycerides and reduce vascular inflammation, while atorvastatin blocks cholesterol synthesis by inhibiting the rate-limiting enzyme HMG-CoA reductase. Together, they provide complementary lipid-lowering and cardioprotective effects for cardiovascular risk reduction.
Approved indications
- Hyperlipidemia and hypertriglyceridemia
- Cardiovascular disease prevention
Common side effects
- Myalgia
- Elevated liver enzymes
- Gastrointestinal upset
- Fish-like aftertaste
Key clinical trials
- Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia (PHASE4)
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (PHASE3)
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (PHASE3)
- Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (PHASE3)
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (PHASE3)
- Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes (PHASE4)
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia (PHASE3)
- Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omega 3-Atorvastatin CI brief — competitive landscape report
- Omega 3-Atorvastatin updates RSS · CI watch RSS
- Seoul National University Bundang Hospital portfolio CI